Regeneron to acquire 2seventy bio’s cancer drug pipeline
Under the agreement, Regeneron will buy full development and commercialisation rights of 2seventy’s pipeline of investigational immune cell…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
31 Jan 24
Under the agreement, Regeneron will buy full development and commercialisation rights of 2seventy’s pipeline of investigational immune cell…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
30 Jan 24
Through the acquisition, Roche gains access to Carmot's comprehensive research and development (R&D) portfolio, encompassing both clinical and…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
25 Jan 24
The integrated business will now serve those with severe diseases, including those caused by genetics, where there is…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
19 Jan 24
Founded in 2019, Summit Biosciences is an intranasal drug-delivery contract development and manufacturing organisation serving the unit dose…
18 Jan 24
In conjunction with the acquisition of PPS, Alcami is enhancing its presence in central North Carolina's pharmaceutical storage…
12 Jan 24
CSI is a clinical CRO that provides cost-effective clinical solutions through its team of experienced clinical research professionals…
10 Jan 24
The acquisition expands GSK’s respiratory pipeline with AIO-001, a phase 2-ready, long-acting antibody targeting the clinically validated TSLP…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
08 Jan 24
In addition to the acquisition of SanReno, Novartis has secured the US FDA approval for commercial manufacturing of…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
03 Jan 24
In preclinical animal trials, the asset showed an excellent safety profile, quick and widespread biodistribution throughout the brain,…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
27 Dec 23
The acquisition adds RayzeBio’s differentiated actinium-based radiopharmaceutical platform, including a pipeline of multiple drug development programmes to BMS’s…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates